About: A rational roadmap for SARS‐CoV‐2/COVID‐19 pharmacotherapeutic research and development. IUPHAR Review 29

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: A rational roadmap for SARS‐CoV‐2/COVID‐19 pharmacotherapeutic research and development. IUPHAR Review 29 Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	A rational roadmap for SARS‐CoV‐2/COVID‐19 pharmacotherapeutic research and development. IUPHAR Review 29
Creator	Levi-Schaffer, Francesca Armstrong, J Davies, J Maguire, Janet Adam, Pawson Alexander, P Alexander, Sph Armstrong, Jane Davenport, A Faccenda, E Harding, S Harding, Simon Janet, Maguire Levi-Schaffer, F Maguire, J Mj, Southan Pawson, A Pawson, Adam Southan, Christopher Steve, Alexander Steve, Spedding
Source	Medline; PMC; WHO
abstract	In this review, we identify opportunities for drug discovery in the treatment of COVID‐19 and in so doing, provide a rational roadmap whereby pharmacology and pharmacologists can mitigate against the global pandemic. We assess the scope for targetting key host and viral targets in the mid‐term, by first screening these targets against drugs already licensed; an agenda for drug re‐purposing, which should allow rapid translation to clinical trials. A simultaneous, multi‐pronged approach using conventional drug discovery methodologies aimed at discovering novel chemical and biological means targetting a short‐list of host and viral entities should extend the arsenal of anti‐SARS‐CoV‐2 agents. This longer‐term strategy would provide a deeper pool of drug choices for future‐proofing against acquired drug resistance. Second, there will be further viral threats, which will inevitably evade existing vaccines. This will require a coherent therapeutic strategy which pharmacology and pharmacologists are best placed to provide.
has issue date	2020-05-01(xsd:dateTime)
bibo:doi	10.1111/bph.15094
bibo:pmid	32358833
has license	no-cc
sha1sum (hex)	9dabd568255d5b9c1238d291ea16b71c1bcd73e9
schema:url	https://doi.org/10.1111/bph.15094
resource representing a document's title	A rational roadmap for SARS‐CoV‐2/COVID‐19 pharmacotherapeutic research and development. IUPHAR Review 29
has PubMed Central identifier	PMC7267163
has PubMed identifier	32358833
schema:publication	Br J Pharmacol
resource representing a document's body	covid:9dabd568255d5b9c1238d291ea16b71c1bcd73e9#body_text
is schema:about of	named entity 'IUPHAR' named entity 'pharmacotherapeutic' named entity 'RNF41' named entity 'glycosyltransferases' named entity 'glycine receptors' named entity 'cytoplasm' named entity 'SARS-CoV-2' named entity 'coronaviruses' named entity 'Mizzen' named entity 'SARS-CoV-2' named entity 'drug target' named entity 'inflammasome' named entity 'ACE2' named entity 'interferon' named entity 'metabolism' named entity 'SARS-CoV' named entity 'glycoproteins' named entity 'molecular mechanism' named entity 'ADAM17' named entity 'sepsis' named entity 'lungs' named entity 'Tipnis' named entity 'treat patients' named entity 'SARS' named entity 'ACE2' named entity 'pIC50' named entity 'cysteine' named entity 'IMPDH2' named entity 'FRET' named entity 'proteinase' named entity 'helicase' named entity 'double-stranded RNA' named entity 'endoribonuclease' named entity 'ACE2' named entity 'protein' named entity 'virus' named entity 'SARS-CoV' named entity 'Philadelphia chromosome' named entity 'SLC6' named entity 'HIV/AIDS' named entity 'pyrrolidine' named entity 'pathology' named entity 'PLpro' named entity 'plasma membranes' named entity 'ACE2' named entity 'model cells' named entity 'SARS coronavirus' named entity 'TBK1' named entity 'positive allosteric modulator' named entity 'benzamidine' named entity 'sofosbuvir' named entity 'glycoprotein' named entity 'functional activity' named entity 'substrates' named entity 'coupled receptor' named entity '0.9' named entity 'MERS-CoV' named entity 'cathepsin' named entity 'PLpro' named entity 'PHARMACOLOGY' named entity 'SARS-CoV-2'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software